Identification of Drug-Disease Associations Using Information of Molecular Structures and Clinical Symptoms via Deep Convolutional Neural Network

Zhanchao Li, Qixing Huang, Xingyu Chen, Yang Wang, Jinlong Li, Yun Xie, Zong Dai, Xiaoyong ZouFrontiers in Chemistry 2020 · DOI

TL;DR

This paper introduces a novel deep learning approach to predict drug-disease associations by combining drug molecular structures and disease clinical symptoms. By representing these relationships as images and feeding them into a convolutional neural network, the method achieves high accuracy in identifying potential new drug uses and lead compounds, offering a powerful tool for drug discovery.

What Problem Does This Paper Address?

The process of discovering new drugs or finding new uses for existing drugs (drug repositioning) is notoriously slow, expensive, and prone to failure. Traditional experimental methods are time-consuming and laborious, making it difficult to explore the vast landscape of potential drug-disease interactions. While computational methods exist, they often struggle with limitations such as relying on specific datasets, lacking uniform similarity definitions, or failing to capture complex relationships. This paper aims to address this by developing a more robust and scalable computational method that leverages both the chemical properties of drugs and the observable characteristics of diseases.

Methods

The core of this research lies in a novel deep learning framework.

  • Feature Extraction: Drugs are characterized by their molecular structures using Pubchem molecular fingerprint descriptors (881-dimensional binary vectors). Diseases are represented by their symptom information, derived from the human symptoms-disease network, resulting in 322-dimensional feature vectors.
  • Data Representation: A unique two-dimensional matrix is constructed for each drug-disease pair. This matrix combines the drug's fingerprint and the disease's symptom features. This matrix is then mapped to a grayscale image.
  • Deep Convolutional Neural Network (CNN): A CNN architecture, optimized for image recognition, is employed to learn patterns from these drug-disease association images. The CNN is trained to classify pairs as either associated or not associated.
  • Negative Sample Generation: To create a balanced dataset for training, negative samples (drug-disease non-associations) are generated by randomly pairing drugs and diseases from the positive set, ensuring they don't exist in known associations. A 1:1 ratio of positive to negative samples is maintained to avoid bias.

Datasets

  • Drug-Disease Associations: The Comparative Toxicogenomics Database (CTD) was used as the primary source for known drug-disease associations. After filtering and curation, 26,521 associations involving 4,501 drugs and 2,093 diseases were obtained.
  • Drug Molecular Structures: Pubchem compound database was used to retrieve SMILES strings for drug molecules.
  • Disease Symptoms: The human symptoms-disease network was used to obtain symptom information for diseases.
  • Independent Test Set: A separate set of 1,323 drug-disease associations was collected from CTD (version June 2019) to provide an unbiased evaluation of the model's predictive power on unseen data.

Key Insights and Ideas

  • Bridging Molecular Structure and Clinical Symptoms: The paper highlights the power of integrating two distinct types of information – the molecular blueprint of a drug and the observable clinical manifestations of a disease – to understand their relationship. This holistic approach moves beyond solely relying on chemical similarity or known targets.
  • Image Representation for Relationships: Transforming complex drug-disease relationships into grayscale images for CNN analysis is a novel and effective way to leverage powerful image recognition architectures for biological data.
  • Pubchem Fingerprint Superiority: Among various molecular fingerprint descriptors tested, the Pubchem fingerprint descriptor demonstrated the best performance, suggesting its suitability for capturing relevant structural information for drug-disease association prediction.
  • Robustness of the Method: The model shows consistent performance across different training/testing splits and even when using a carefully constructed independent test set, indicating its reliability and generalizability.

Key Results

  • High Predictive Accuracy: The model achieved an accuracy of 89.90% on the training set and 86.51% on the test set.
  • Effective for New Indications: The method demonstrated strong performance in identifying potential new drug indications and lead compounds, with accuracies consistently above 70% even on an independent test set.
  • Large-Scale Prediction: The model was used to predict over 3.6 million potential drug-disease associations, with a subset of these further validated through molecular docking simulations.
  • Performance Metrics: Beyond accuracy, the model also achieved high scores in sensitivity, specificity, precision, MCC, AUCR, and AUCP, indicating a well-balanced and robust predictive capability.

Limitations and Future Work

  • Negative Sample Generation: While the 1:1 ratio of positive to negative samples is a standard approach, the method for generating negative samples is heuristic and might not perfectly represent true non-associations.
  • Dataset Dependency: The performance is inherently tied to the quality and completeness of the CTD database. Gaps or biases in the database could affect predictions.
  • Future Work: The authors suggest that the proposed method can be a powerful tool for large-scale virtual screening in drug research and development. Further experimental validation of the predicted associations is crucial. The source code is available, encouraging further research and application.

Summary updated

Abstract

Identifying drug-disease associations is helpful for not only predicting new drug indications and recognizing lead compounds, but also preventing, diagnosing, treating diseases. Traditional experimental methods are time consuming, laborious and expensive. Therefore, it is urgent to develop computational method for predicting potential drug-disease associations on a large scale. Herein, a novel method was proposed to identify drug-disease associations based on the deep learning technique. Molecular structure and clinical symptom information were used to characterize drugs and diseases. Then, a novel two-dimensional matrix was constructed and mapped to a gray-scale image for representing drug-disease association. Finally, deep convolution neural network was introduced to build model for identifying potential drug-disease associations. The performance of current method was evaluated based on the training set and test set, and accuracies of 89.90 and 86.51% were obtained. Prediction ability for recognizing new drug indications, lead compounds and true drug-disease associations was also investigated and verified by performing various experiments. Additionally, 3,620,516 potential drug-disease associations were identified and some of them were further validated through docking modeling. It is anticipated that the proposed method may be a powerful large scale virtual screening tool for drug research and development. The source code of MATLAB is freely available on request from the authors.
BibTeX
@inproceedings{li2020identification,
  author = {Zhanchao Li and Qixing Huang and Xingyu Chen and Yang Wang and Jinlong Li and Yun Xie and Zong Dai and Xiaoyong Zou},
  title = {{Identification of Drug-Disease Associations Using Information of Molecular Structures and Clinical Symptoms via Deep Convolutional Neural Network}},
  booktitle = {Frontiers in Chemistry},
  year = {2020},
  doi = {10.3389/fchem.2019.00924},
}
Figure